AKTX Akari Therapeutics, Plc
Healthcare$17.81-2.52%ClosedMarket Cap: $20.4M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
0.03
P/S
0.00
EV/EBITDA
-0.65
DCF Value
$-13.95
FCF Yield
-52.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-123.3%
ROA
-82.8%
ROIC
-130.5%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | NaN% | $-15.8M | $-14.5M | $— | — |
| Q4 null | $0.00 | NaN% | $-3.2M | $-5.3M | $— | — |
| FY null | $0.00 | NaN% | $-17.3M | $-17.3M | $— | — |
| Q3 null | $0.00 | NaN% | $-7.4M | $-6.4M | $— | — |
| Q2 null | $0.00 | NaN% | $-3.1M | $-1.9M | $— | — |
| Q1 null | $0.00 | NaN% | $-3.5M | $-3.7M | $— | — |
| Q4 null | $0.00 | NaN% | $-5.3M | $-3.8M | $— | — |
| FY null | $0.00 | NaN% | $-21.6M | $-19.8M | $— | — |
| Q3 null | $0.00 | NaN% | $-2.9M | $-2.9M | $— | — |
| Q2 null | $0.00 | NaN% | $-7.4M | $-7.6M | $— | — |
| Q1 null | $0.00 | -Infinity% | $-6.0M | $-5.6M | $— | — |
| Q4 2023 | $0.00 | NaN% | $-5.1M | $-4.1M | $-2.40 | — |